Inhibrx Biosciences, Inc. (INBX)
NASDAQ · Healthcare
$84.09-3.78%
As of Jul 20, 2026
Price history
Key statistics
- Market cap
- $1.52B
- P/E ratio
- —
- EPS
- —
- Volume
- 352,154
- 52-week high
- —
- 52-week low
- —
- Open
- $87.53
- Day high
- $87.93
- Day low
- $83.28
Financial highlights
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| 2025 | $1.3M | -$140.06M | -$9.04 |
| 2024 | $200K | $1.69B | $112.62 |
| 2023 | $1.8M | -$241.36M | -$20.48 |
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
- CEO
- Mark Lappe
- Employees
- 109
- Country
- US
- IPO date
- May 29, 2024
Similar stocks
Other Healthcare companies
Frequently asked questions
- What is Inhibrx Biosciences, Inc.'s stock price today?
- INBX is trading at $84.09 as of Jul 20, 2026.
- What is Inhibrx Biosciences, Inc.'s market cap?
- Inhibrx Biosciences, Inc. (INBX) has a market capitalization of $1.52B.
- Does Inhibrx Biosciences, Inc. pay a dividend?
- Inhibrx Biosciences, Inc. did not pay a dividend in its most recent reported fiscal year.
- What sector is Inhibrx Biosciences, Inc. in?
- Inhibrx Biosciences, Inc. operates in the Healthcare sector.